Biomarin
BMRN
Biomarin (BMRN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.20
- EPS estimate
- $0.95
- EPS surprise
- +26.98%
- Revenue surprise
- +6.19%
- Revenue
- $989.7M
- Revenue estimate
- $932.0M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $0.95 | $1.20 | +26.98% | $989.7M | SEC |
| Q1 2026 | May 4, 2026 | $0.69 | $0.76 | +9.59% | $766.0M | SEC |
| Q4 2025 | Feb 23, 2026 | $0.17 | −$0.24 | −241.68% | $874.6M | SEC |
| Q3 2025 | Oct 27, 2025 | −$0.28 | −$0.16 | +42.88% | $776.1M | SEC |
| Q2 2025 | Aug 4, 2025 | $0.86 | $1.23 | +42.89% | $825.0M | SEC |
| Q1 2025 | May 1, 2025 | $0.71 | $0.95 | +33.03% | $745.1M | SEC |
| Q4 2024 | Feb 19, 2025 | $0.53 | $0.64 | +19.85% | $747.0M | SEC |
| Q3 2024 | Oct 29, 2024 | $0.53 | $0.55 | +3.58% | $745.7M | SEC |
| Q2 2024 | Aug 5, 2024 | $0.36 | $0.55 | +53.72% | $712.0M | SEC |
| Q1 2024 | Apr 24, 2024 | $0.31 | $0.46 | +47.53% | $648.8M | SEC |
| Q4 2023 | Feb 22, 2024 | $0.20 | $0.11 | −44.22% | $646.2M | SEC |
| Q3 2023 | Nov 1, 2023 | $0.22 | $0.21 | −4.33% | $581.3M | SEC |
| Q2 2023 | Jul 31, 2023 | $0.21 | $0.29 | +37.18% | $595.3M | SEC |
| Q1 2023 | Apr 26, 2023 | $0.16 | $0.27 | +74.08% | $596.4M | SEC |
| Q4 2022 | Feb 27, 2023 | −$0.06 | $0.00 | +100.00% | $537.5M | SEC |
| Q3 2022 | Oct 26, 2022 | −$0.01 | −$0.04 | −233.33% | $505.3M | SEC |
| Q2 2022 | Aug 3, 2022 | $0.03 | $0.15 | +355.93% | $533.8M | SEC |
| Q1 2022 | Apr 27, 2022 | $0.21 | $0.63 | +196.47% | $519.4M | SEC |
| Q4 2021 | Feb 23, 2022 | −$0.36 | −$0.32 | +11.72% | $449.8M | SEC |
| Q3 2021 | Oct 27, 2021 | −$0.25 | −$0.20 | +20.03% | $408.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Biomarin (BMRN) last report earnings?
Biomarin last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did BMRN beat earnings estimates?
Yes. Biomarin reported EPS of $1.20 for Q2 2026 against a $0.95 estimate — a 26.98% beat.
How much revenue did BMRN report last quarter?
Biomarin reported $989.7M in revenue for Q2 2026, against a consensus estimate of $932.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.